Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia GravisMuscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndromeActive, not recruitingPhase 1 / Phase 22026-06-09NCT06106672

1 results · Page 1 of 1

Swipe the table sideways for more columns.

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Atlantis ResearchMiamiUnited States1
Barrow Neurological InstitutePhoenixUnited States50
Infusion for HealthBreaUnited States1
Insight Hospital and Medical CenterChicagoUnited States1
Insight Research Institute, DearbornDearbornUnited States1
Medical University of South CarolinaCharlestonUnited States628
Nerve and Muscle Center of TexasHoustonUnited States8
Ohio State University Wexner Medical CenterColombusUnited States1
Prolato Clinical Research CenterHoustonUnited States22
Quantix Research, LLCMiamiUnited States1
University of California, DavisSacramentoUnited States49
University of California, IrvineOrangeUnited States29
University of Kansas Medical CenterKansas CityUnited States240
University of Missouri, NextGen Precision HealthColumbiaUnited States1
University of South FloridaTampaUnited States73
Virginia Commonwealth UniversityRichmondUnited States156
Yale UniversityNew HavenUnited States1